Noida and Greater Noida form the eastern flank of the National Capital Region, situated in Gautam Buddh Nagar district of Uttar Pradesh. Unlike Delhi, which hosts the federally funded a tertiary cancer centre Dr BRA-IRCH and NCI Jhajjar, and unlike Gurgaon, which has a concentrated expressway corridor of private tertiary hospitals, Noida’s oncology capacity has grown around a mix of multi-specialty private hospitals spread across sectors in Noida proper and the newer Knowledge Park and expressway campuses in Greater Noida. There is no standalone government cancer centre within Gautam Buddh Nagar. For public-sector tertiary oncology, Noida residents are routed across the Yamuna to a tertiary cancer centre Delhi and Dr BRA-IRCH, to the Delhi State Cancer Institute at Dilshad Garden, or to a tertiary cancer centre at Rohini, all within 25 to 40 kilometres depending on the sector of origin. The district does host ICMR-National Institute of Cancer Prevention and Research (ICMR-NICPR) at Sector 39, which runs the Population Based Cancer Registry for Gautam Buddh Nagar, conducts community screening camps at primary health centres and community health centres, and carries out translational cancer prevention research. This page is a directory and a decision aid for patients and families in Noida or Greater Noida who have a suspicion, a biopsy result, or a confirmed diagnosis and need to decide where to go, how the system works, what it costs, and which entitlements to stack. (See the ICMR-NCDIR cancer registries, the GLOBOCAN 2022 India fact sheet, and the ICMR-NICPR Gautam Buddh Nagar PBCR.)
What This Page Is: Cancer Care in Noida From First Suspicion to Follow-Up
Cancer incidence in Gautam Buddh Nagar is tracked by the Population Based Cancer Registry (PBCR) started in 2017 under ICMR-NICPR at Sector 39 in Noida, covering both urban Noida and rural parts of the district. A full Three Year Report from this registry has not yet been published, so the nearest published incidence data comes from PBCR Delhi and the Varanasi district PBCR in eastern UP, alongside the ICMR-NCDIR Report on Cancer Burden in India 2020 and the NCRP cancer incidence estimates for 2022 (see ICMR-NCDIR PBCR summary tables and GLOBOCAN 2022). Uttar Pradesh carries the largest absolute number of cancer cases of any Indian state, estimated at 14.4 per cent of the national total per NCRP 2022 estimates. GLOBOCAN 2022 estimates approximately 1.41 million new cancers and 920,000 deaths nationally.
This page does not rank hospitals. It explains which Noida institutions carry which tumour-board strengths, how the public pathway through a tertiary cancer centre Delhi works for a Gautam Buddh Nagar resident, what the average out-of-pocket cost bands look like for the commonest treatments, and which entitlements a Noida resident can layer: Ayushman Bharat PMJAY, CGHS, ESIC, the UP Mukhyamantri Jan Arogya Yojana, the Health Minister’s Cancer Patient Fund, and Rashtriya Arogya Nidhi.
Who Treats Cancer in Noida: Three Institutional Layers
Noida’s oncology ecosystem divides into three layers, because the public tertiary oncology layer within the district itself is structurally thin. The first layer is the public-sector and research layer: Noida residents needing government-funded cancer treatment are referred across the Yamuna to a tertiary cancer centre Delhi (Dr BRA-IRCH, NCI Jhajjar), a tertiary cancer centre, the Delhi State Cancer Institute at Dilshad Garden, or a tertiary cancer centre at Rohini. Within the district, ICMR-NICPR at Sector 39 provides screening and cancer registration but not treatment. The second layer is the private tertiary layer within Noida city: a leading cancer centre at Sector 62, a leading cancer centre Hospital at Sector 128, Metro Hospitals and Heart Institute at Sector 11, Yatharth Super Speciality Hospital at Sector 110, a leading cancer centre at Sector 128, Felix Hospital at Sector 137, and Kailash Hospital at Sector 27. The third layer is the Greater Noida extension: Sharda Hospital at Knowledge Park III, NuMed Super Speciality Hospital, and Prakash Hospital. For modalities that no Noida hospital currently offers at scale, such as proton therapy, patients are referred to a leading cancer centre Proton Cancer Centre in Chennai. The sections below walk through each layer so that a family can build an informed shortlist before the first appointment.
Public-Sector Referral Pathway: a tertiary cancer centre Delhi, NCI Jhajjar, a tertiary cancer centre, and a tertiary cancer centre for Gautam Buddh Nagar Residents
The Government District Hospital at Sector 30, Gautam Buddh Nagar, is the primary public healthcare facility in the district, but it does not run a dedicated cancer treatment service with chemotherapy, radiation, or surgical oncology. For tertiary public-sector cancer care, Noida residents are referred to a tertiary cancer centre Delhi (Dr BRA-IRCH on the Ansari Nagar campus, operational since 1984, providing surgical, medical, and radiation oncology with a dedicated paediatric haematology-oncology service), the newer a tertiary cancer centre NCI Jhajjar campus commissioned in phases from 2019 with proton planning capability and advanced radiotherapy bunkers, a tertiary cancer centre which runs medical and radiation oncology with brachytherapy, and a tertiary cancer centre Medical College which handles gynaecologic and breast oncology load (see NCI a tertiary cancer centre campus details and a tertiary cancer centre institutional page). The Delhi State Cancer Institute (a tertiary cancer centre) at Dilshad Garden and a tertiary cancer centre at Rohini are also within 25 to 40 kilometres of most Noida sectors. The referral chain typically starts with a consultation at the district hospital or a community health centre, where patients with a suspected malignancy are given a referral letter for a tertiary cancer centre or another tertiary centre. Registration at a tertiary cancer centre requires an OPD card and, for concessional care, an address proof and income certificate. Uttar Pradesh residents are eligible for a tertiary cancer centre services but are not covered by Delhi-specific schemes such as the Delhi Arogya Kosh (see DGHS Delhi operational guidelines).
ICMR-NICPR Noida: Cancer Screening, Registry, and Prevention Research at Sector 39
A distinctive feature of the Noida oncology ecosystem is the presence of ICMR-National Institute of Cancer Prevention and Research (ICMR-NICPR) at Sector 39, formerly the Institute of Cytology and Preventive Oncology. NICPR runs the Population Based Cancer Registry for Gautam Buddh Nagar, started in 2017, which covers both urban Noida and rural parts of the district. NICPR also conducts community-based cancer screening camps at primary health centres and community health centres across Gautam Buddh Nagar, screening for oral cancer by visual examination, breast cancer by clinical breast examination, and cervical cancer by Pap smear and VIA, in collaboration with the Chief Medical Officer’s office. These camps are free and open to all Gautam Buddh Nagar residents (see ICMR-NICPR PBCR and NICPR screening camps). NICPR is not a treatment hospital; it does not admit patients for chemotherapy, surgery, or radiation, but it is a screening and referral resource for the district, and can refer patients with screen-detected abnormalities to tertiary centres in Noida or Delhi for diagnostic workup and treatment.
Private Tertiary Oncology in Noida: a leading cancer centre, a leading cancer centre, Metro, Yatharth, a leading cancer centre, Felix, and Kailash
a leading cancer centre at Sector 62, through its partnership with International Oncology, has operated a dedicated cancer care unit for over fifteen years, with a 40-bedded day-care chemotherapy facility, PET-CT, nuclear medicine, and linear accelerators for radiation oncology, alongside surgical oncology including laparoscopic and open procedures (see a leading cancer centre Cancer Institute Noida). a leading cancer centre Hospital at Sector 128 is the newest and most equipment-intensive oncology platform in Noida, carrying the Da Vinci Xi robotic surgery platform, TrueBeam STx linear accelerator for IMRT, VMAT, SBRT, and SRS, HDR brachytherapy, 3T MRI, 128-slice CT, dual-head SPECT-CT, a 64-slice PET-CT with flow motion technology, digital mammography with tomosynthesis, and a bone marrow transplant programme under the haematology and BMT department (see a leading cancer centre Noida). Metro Hospitals and Heart Institute at Sector 11, operational for over 27 years, runs a cancer care department with medical, surgical, and radiation oncology, a bone marrow transplant unit, theranostics, PET-CT, and TrueBeam LINAC (see Metro Hospitals cancer care). Yatharth Super Speciality Hospital at Sector 110 operates a Centre for Cancer and Bone Marrow Transplant covering prevention through palliative care, with IMRT, IGRT, and SBRT capability (see Yatharth cancer centre). a leading cancer centre at Sector 128, established in 2014, provides medical, surgical, and radiation oncology. Felix Hospital at Sector 137 runs a medical oncology and haematology-blood cancer service (see Felix oncology). Kailash Hospital at Sector 27, NABH-accredited with 325 beds including 140 ICU beds, carries medical oncology and head-and-neck oncology consultants.
Greater Noida Extension: Sharda Hospital, NuMed, and Emerging Capacity
Sharda Hospital at Knowledge Park III in Greater Noida, affiliated with Sharda University, is a 1,200-plus-bed multi-super-speciality hospital that runs an Institute of Cancer with medical, surgical, radiation, paediatric, head-and-neck, and gynaecologic oncology. Sharda also has a molecular pathology laboratory, PET-CT, and digital mammography (see Sharda Institute of Cancer). NuMed Super Speciality Hospital in Greater Noida provides medical oncology for breast, lung, blood, and gastrointestinal cancers. Prakash Hospital carries a medical oncology service. For capital-intensive modalities that no Greater Noida hospital currently offers, including proton therapy, CyberKnife, and MRI-LINAC, patients are referred to Delhi or Gurgaon NCR centres or to a leading cancer centre Proton Cancer Centre in Chennai. For complex bone marrow transplant cases including haplo-identical and cord blood transplants, referral to a tertiary cancer centre ACTREC in Navi Mumbai or a tertiary cancer centre Delhi BMT remains an established route (see a tertiary cancer centre institutional page).
NCR Cross-Referral Network: Delhi and Gurgaon Tertiary Centres and Proton Therapy Referral
Noida families routinely include Delhi and Gurgaon hospitals in their shortlist because the NCR commuter corridor places these within 30 to 60 minutes of most Noida sectors. In Delhi, a tertiary cancer centre at Rohini, a leading cancer centre Saket, a leading cancer centre Patparganj, a leading cancer centre at Pusa Road, a leading cancer centre Shalimar Bagh, a leading cancer centre at Rajinder Nagar, a leading cancer centre at Vasundhara Enclave, and a leading cancer centre Indraprastha at Sarita Vihar all accept Noida patients. In Gurgaon, a leading cancer centre The Medicity at Sector 38, a leading cancer centre at Sector 51, and a leading cancer centre (a leading cancer centre) at Sector 44 carry robotic surgery, CyberKnife, and high-volume radiation oncology units. a leading cancer centre Dwarka serves south-west Delhi and Noida families. For proton therapy, which is not yet available anywhere in NCR, patients are referred to a leading cancer centre Proton Cancer Centre in Chennai under the PTCOG referral framework for paediatric CNS tumours, skull base chordomas, sinonasal cancers, and re-irradiation cases (see NCI PDQ proton beam therapy referral indications). For bone marrow transplant volumes, the a tertiary cancer centre ACTREC in Navi Mumbai remains a national reference alongside Delhi NCR units (see a tertiary cancer centre institutional page).
Cancer Types and Subtypes Most Commonly Treated in Noida
Noida does not yet have published site-specific incidence tables from its own Gautam Buddh Nagar PBCR, which began data collection in 2017 and has not yet released a full Three Year Report. The nearest published PBCR data comes from PBCR Delhi and, for broader context, the Varanasi district PBCR in eastern UP. The ICMR-NCDIR Report on Cancer Burden in India 2020 and the NCRP cancer incidence estimates for 2022, together with GLOBOCAN 2022 India, provide the regional framework (see ICMR-NCDIR PBCR summary tables and Pandey et al., Varanasi PBCR). The leading cancer sites in women nationally are breast (28.8 per cent of female cancers), cervix uteri (10.6 per cent), and ovary (6 per cent); in men the leading sites are lung (10.6 per cent), mouth (8.4 per cent), prostate (6.1 per cent), tongue (5.9 per cent), and stomach (4.8 per cent). In the Varanasi PBCR, the commonest cancers in women are breast, cervix uteri, and gallbladder, and in men mouth and tongue cancers predominate, reflecting the high smokeless tobacco prevalence in UP. Noida’s case mix, given its urban high-income catchment overlapping with the Delhi metropolitan area, is likely weighted toward the same profile as Delhi PBCR: breast, lung, colorectal, head and neck, prostate, gynaecologic, and haematological cancers, plus an elevated gallbladder cancer rate characteristic of the Ganga basin catchment. Within each tumour type, Noida’s tertiary hospitals that run molecular pathology, notably a leading cancer centre Sector 128, a leading cancer centre Sector 62, and Metro Sector 11, cover the subtype classifications of the WHO Classification of Tumours, 5th edition.
Molecular and Biomarker Testing Available in Noida and Through NCR Referral
Biomarker-driven treatment selection is standard at Noida’s tertiary hospitals with molecular pathology capability: a leading cancer centre Sector 128, a leading cancer centre Sector 62, Metro Sector 11, and Sharda Greater Noida. For breast carcinoma, reflex panels include ER, PR, HER2, and Ki-67, with HER2-low recognised per ASCO/CAP 2023 to enable trastuzumab deruxtecan eligibility. Lung adenocarcinoma is reflex tested for EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK1/2/3, HER2, and PD-L1 22C3 CPS using NGS panels available at a leading cancer centre Sector 128 molecular pathology, a leading cancer centre Sector 62, Sharda molecular pathology laboratory, and through external referral to MedGenome, Strand Life Sciences, accredited diagnostic laboratories, and accredited diagnostic laboratories. Colorectal carcinoma is reflex tested for MMR by IHC with reflex BRAF V600E and MLH1 methylation, plus extended RAS, BRAF, HER2, and NTRK in metastatic disease. Gastric carcinoma is reflex tested for HER2 IHC with FISH, MMR, PD-L1 22C3 CPS, and Claudin 18.2 on managed access. Endometrial carcinoma uses the TCGA-aligned ProMisE classifier with POLE sequencing, MMR IHC, and p53 IHC. Blood cancers are categorised by WHO HAEM5 and risk-stratified by ELN 2022 for AML, IMWG for myeloma, and CLL-IPI for chronic lymphocytic leukaemia (see ESMO clinical practice guidelines and NCCN guidelines).
Symptoms and Red Flags: When a Noida Resident Should Seek Oncology Referral
This section lists the symptom patterns for which the NCI PDQ summaries, the a tertiary cancer centre EBM manuals, and the ESMO patient guides recommend prompt specialist evaluation, annotated with how care is accessed from Noida specifically. A breast lump, bloody or single-sided nipple discharge, skin dimpling, or a newly inverted nipple warrants same-week referral to a breast clinic: a leading cancer centre Sector 62, a leading cancer centre Sector 128, Metro Sector 11, or Yatharth Sector 110 in the private pathway, or Dr BRA-IRCH at a tertiary cancer centre, a tertiary cancer centre, or a tertiary cancer centre in the public pathway across the Yamuna. A triple assessment of clinical examination, imaging, and core biopsy is the standard per a tertiary cancer centre Breast EBM, and the private Noida centres with dedicated breast units typically complete this within two to three visits.
Persistent cough lasting more than three weeks, blood in sputum, or unexplained weight loss in a current or former smoker, including bidi and hookah users, should prompt a chest X-ray and if abnormal a contrast CT of thorax and upper abdomen. Noida and Greater Noida share the NCR air pollution burden: annual mean PM2.5 concentrations have consistently exceeded the WHO Air Quality Guideline by several multiples, which is relevant background exposure for Noida residents presenting with respiratory symptoms even without tobacco use (see IARC Monograph 109 on outdoor air pollution). Postcoital bleeding, intermenstrual bleeding, or any postmenopausal bleeding is an immediate referral to gynaecologic oncology: a leading cancer centre Sector 128, a leading cancer centre Sector 62, and Sharda Greater Noida in the private pathway, or a tertiary cancer centre, a tertiary cancer centre, and a tertiary cancer centre in the public pathway. A change in bowel habit lasting more than four weeks, rectal bleeding, or iron deficiency anaemia in a man or postmenopausal woman should prompt a colonoscopy at a leading cancer centre Sector 128, a leading cancer centre Sector 62, Metro Sector 11, or a leading cancer centre Sector 128. Painless progressive jaundice with a palpable gallbladder is urgent because gallbladder cancer is among the commonest GI cancers in women in Uttar Pradesh, with the Varanasi PBCR data confirming elevated rates (see Pandey et al., Varanasi PBCR and Randi et al., gallbladder cancer epidemiology). Painless lymphadenopathy lasting more than four weeks with B symptoms is a haematology referral, and excision biopsy rather than FNAC alone is the standard per the Lugano classification and WHO HAEM5. A non-healing mouth ulcer, white or red patch inside the mouth, or progressive trismus lasting more than two to three weeks warrants biopsy referral, since oral submucous fibrosis from smokeless tobacco use is widespread in UP (see smokeless tobacco and oral malignancy systematic review). Paediatric presentations with unexplained pallor, bruising, bone pain, or an abdominal mass should be referred to a tertiary cancer centre paediatric haematology-oncology, a tertiary cancer centre, a leading cancer centre paediatric BMT in Delhi, or Sharda paediatric oncology in Greater Noida (see MoHFW Patient Rights Charter).
Air Pollution, Tobacco, and Noida-Specific Cancer Risk Factors
Tobacco, smoked and smokeless, remains the single largest attributable cause of cancer in Uttar Pradesh. Smokeless tobacco products including gutkha, khaini, zarda, and paan masala drive a disproportionate share of oral cavity cancer in the state, with gutkha carrying an odds ratio of approximately 8.67 for oral cancer risk per a systematic review of Indian studies; although gutkha has been banned across India, enforcement remains patchy and consumption persists in UP’s semi-urban and rural populations (see smokeless tobacco systematic review and IARC Monographs 83, 89, and 100E). Bidi smoking and hookah use contribute to lung, larynx, and hypopharynx cancers. The Global Adult Tobacco Survey 2016-17 placed Uttar Pradesh among the states with high adult tobacco use prevalence.
Ambient air pollution is a Group 1 carcinogen for lung cancer per IARC Monograph 109. Noida falls within the NCR air quality zone, and studies of PM2.5 composition identify vehicular emissions, biomass burning, construction dust, and industrial sources as leading contributors. Seasonal crop residue burning from Punjab and Haryana compounds the baseline load in October through December. The Lancet Commission on Pollution and Health and its 2022 update estimated that ambient and household air pollution together contribute a measurable fraction of India’s lung cancer burden, with the fraction higher in the NCR than the national average. Dietary and metabolic factors, obesity, type 2 diabetes, and physical inactivity are rising in Noida and are implicated in breast, endometrial, colorectal, kidney, pancreas, liver, and gallbladder cancers per IARC Handbook of Cancer Prevention Volume 16. HPV remains the cause of effectively all cervical cancers and a growing fraction of oropharyngeal cancers; Hepatitis B and C are relevant for the liver cancer caseload. Occupational exposures are under-recognised in Noida’s industrial and construction sectors; Gautam Buddh Nagar hosts multiple industrial estates at Noida Phase I and II and Greater Noida, with manufacturing in electronics, chemicals, textiles, and construction materials where asbestos, silica, diesel exhaust, and formaldehyde are documented carcinogens per IARC Monographs 100C, 100F, and 118. The practical takeaway for a Noida resident: tobacco cessation (smoked and smokeless), HPV vaccination including CERVAVAC for girls 9-14 and boys up to 26, Hepatitis B vaccination, weight management, and minimising outdoor exposure during severe air quality episodes together account for most modifiable risk. For screening, ICMR-NICPR’s community screening camps at PHCs and CHCs in Gautam Buddh Nagar offer oral visual inspection, clinical breast examination, and VIA cervical screening (see NICPR screening programme and WHO air quality guidelines).
How a New Cancer Diagnosis Unfolds in Noida: Public and Private Pathways
Diagnosis in Noida follows a tiered pathway. First contact is most often a general physician, gynaecologist, ENT surgeon, or pulmonologist at a private clinic, a CGHS wellness centre, an ESIC dispensary, or the Government District Hospital at Sector 30. Suspicion of cancer triggers referral to a tertiary oncology unit. In the private pathway this means the cancer care departments at a leading cancer centre Sector 62, a leading cancer centre Sector 128, Metro Sector 11, Yatharth Sector 110, a leading cancer centre Sector 128, or Sharda Greater Noida. In the public pathway, because Gautam Buddh Nagar has no government tertiary cancer centre, referral crosses the Yamuna to a tertiary cancer centre Dr BRA-IRCH, NCI Jhajjar, a tertiary cancer centre at Dilshad Garden, a tertiary cancer centre at Rohini, or a tertiary cancer centre (see NCI a tertiary cancer centre and a tertiary cancer centre). Tissue diagnosis is mandatory before any cancer-directed treatment, in line with the a tertiary cancer centre EBM framework and ESMO and NCCN guidance.
Tissue Diagnosis, Histopathology, and Immunohistochemistry in Noida
Core needle biopsy under ultrasound or CT guidance is the workhorse for breast, liver, lung, and soft tissue masses at a leading cancer centre Sector 128, a leading cancer centre Sector 62, Metro Sector 11, and a leading cancer centre Sector 128. Endoscopic biopsy covers upper and lower GI lesions at all four centres. EUS-FNA for pancreatic and submucosal lesions is available at a leading cancer centre Sector 128 and through NCR referral at a tertiary cancer centre Gastroenterology, a leading cancer centre, and a leading cancer centre. Bronchoscopy with EBUS-TBNA for mediastinal lymph node sampling in lung cancer staging is available at a leading cancer centre Sector 128 and a leading cancer centre Sector 62, with referral to a tertiary cancer centre Pulmonary Medicine and a tertiary cancer centre for complex cases. Cytology has a defined role for thyroid (FNAC under USG, Bethesda system), serous effusions, and cervical liquid-based cytology with reflex high-risk HPV DNA testing at a leading cancer centre, a leading cancer centre, and private NCR laboratories (see WHO cervical screening guideline 2021).
Histopathology is reported using the WHO Classification of Tumours 5th edition and CAP synoptic templates. Standard reflex IHC panels at Noida pathology services include ER, PR, HER2, and Ki-67 for breast carcinoma, with HER2-low recognised per ASCO/CAP 2023 to enable trastuzumab deruxtecan eligibility. Lung adenocarcinoma is reflex tested for EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK1/2/3, HER2, and PD-L1 22C3 CPS using NGS panels at a leading cancer centre Sector 128 molecular pathology, a leading cancer centre Sector 62, Sharda molecular pathology laboratory, and through external referral to MedGenome, Strand Life Sciences, accredited diagnostic laboratories, and accredited diagnostic laboratories. Colorectal carcinoma uses universal MMR IHC with reflex BRAF V600E and MLH1 methylation. Gastric carcinoma is reflex tested for HER2 with FISH, MMR, PD-L1 22C3 CPS, and Claudin 18.2. Haematolymphoid disease is worked up with flow cytometry, conventional cytogenetics, FISH, and targeted molecular panels mapped to WHO HAEM5 and ELN 2022. Metro Sector 11 and a leading cancer centre Sector 128 carry in-house haematology and BMT services with onsite flow cytometry; for complex molecular haematology panels, specimens are referred to a tertiary cancer centre, a tertiary cancer centre, or accredited NCR laboratories (see NCI PDQ diagnostic guidance).
Imaging and Nuclear Medicine: PET-CT, MRI, and PSMA Scans in Noida
Imaging in Noida is delivered across 1.5T and 3T MRI platforms, 64 to 256-slice CT, dedicated digital mammography, and PET-CT. a leading cancer centre Sector 128 operates a 64-slice PET-CT with flow motion technology, 3T MRI, 128-slice CT, and digital mammography with tomosynthesis. a leading cancer centre Sector 62 carries PET-CT and nuclear medicine. Metro Sector 11 operates PET-CT and TrueBeam-integrated imaging. FDG PET-CT for staging and response assessment is available at all three centres. PSMA PET-CT for prostate cancer staging, validated by the proPSMA randomised trial referenced in NCI PDQ, is available at a leading cancer centre Sector 128 and through NCR referral at a tertiary cancer centre Nuclear Medicine, INMAS, a tertiary cancer centre, a leading cancer centre, and Mahajan Imaging. DOTANOC/DOTATATE PET-CT for neuroendocrine tumours is available through NCR referral at a tertiary cancer centre, INMAS, a tertiary cancer centre, and a leading cancer centre. Whole-body MRI for myeloma per IMWG is available at a leading cancer centre Sector 128 and through NCR referral at a tertiary cancer centre, a tertiary cancer centre, and a leading cancer centre. Mammography screening for women aged 40 and older follows the ACR BI-RADS reporting framework at a leading cancer centre Sector 128, a leading cancer centre Sector 62, and Sharda Greater Noida. Cervical screening uses VIA at ICMR-NICPR community camps at PHCs and CHCs, and liquid-based cytology with HPV DNA testing at a leading cancer centre, a leading cancer centre, and private NCR laboratories. Faecal immunochemical testing and colonoscopy for symptomatic and high-risk screening are deployed at a leading cancer centre Sector 128, a leading cancer centre Sector 62, Metro Sector 11, and a leading cancer centre Sector 128 (see ESMO screening guidance).
Genetic Counselling and Hereditary Cancer Testing in Noida and NCR
Genetic counselling and germline testing for hereditary cancer syndromes are not offered as a standalone service at most Noida hospitals but are accessed through NCR referral pathways. The a tertiary cancer centre Genetics Clinic, a tertiary cancer centre Cancer Genetics Clinic with Delhi NCR referral, a tertiary cancer centre Genetic Counselling Service, and a leading cancer centre Genomics run panels covering BRCA1/BRCA2, PALB2, ATM, CHEK2, TP53, PTEN, STK11, CDH1, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, and MUTYH per NCCN Genetic/Familial High-Risk Assessment and ESMO guidance. a leading cancer centre Sector 128 can initiate germline testing through its molecular pathology unit and external laboratory partnerships. In Noida, a patient with triple-negative breast cancer under 60, ovarian cancer at any age, pancreatic cancer with a family history, or early-onset colorectal cancer should ask the treating oncologist for a genetics referral, since a positive result changes treatment (PARP inhibitors for BRCA-mutant tumours) and alters surveillance for the entire family.
Staging Systems Used by Noida Tumour Boards
Solid tumours managed at Noida tertiary hospitals are staged using the AJCC/UICC TNM 8th edition, applied through multidisciplinary tumour boards at a leading cancer centre Sector 128, a leading cancer centre Sector 62, Metro Sector 11, Yatharth Sector 110, and Sharda Greater Noida, in line with ESMO and NCCN recommendations and the a tertiary cancer centre framework. Site-specific frameworks layered onto TNM include AJCC prognostic stage groups for breast cancer incorporating ER, PR, HER2, and grade; FIGO 2018 for cervical, endometrial, ovarian, vulvar, and vaginal cancers with imaging upgrade for IIIC1/IIIC2 cervical; BCLC for hepatocellular carcinoma; Lugano classification with PET-CT Deauville response assessment for lymphoma; IPI, FLIPI, MIPI, and IPSS-R for lymphoma and MDS; R-ISS for myeloma; ELN 2022 for AML; Rai/Binet for CLL; and separate AJCC TNM 8 schema for HPV-positive oropharyngeal carcinoma using p16 IHC. Prostate cancer uses NCCN very-low through very-high risk combined with EAU groupings, mpMRI PI-RADS v2.1, and PSMA PET-CT. Paediatric solid tumours follow Toronto/SIOP and COG risk stratification through referral to leading cancer centres Paediatric Haemato-Oncology, and Sharda Greater Noida. For complex or rare tumour types, Noida oncologists can refer cases for a second tumour-board opinion at leading cancer centres in the region, or a leading cancer centre Saket in the wider NCR (see NCI PDQ staging summaries).
Surgical Oncology in Noida: Open, Laparoscopic, and Robotic Procedures
a leading cancer centre Sector 128 carries the Da Vinci Xi robotic surgery platform and offers robot-assisted radical prostatectomy with extended pelvic lymph node dissection per ProtecT and EAU guidance, robotic lobectomy per CALGB 140503, robotic radical and partial nephrectomy, robotic low anterior resection with TME, and robotic radical hysterectomy. a leading cancer centre Sector 62, through International Oncology, provides open and laparoscopic surgical oncology for breast, gastrointestinal, gynaecologic, head-and-neck, and urologic malignancies. Metro Sector 11 runs surgical oncology alongside its BMT programme. Yatharth Sector 110, a leading cancer centre Sector 128, Felix Sector 137, and Sharda Greater Noida run general surgical oncology services for common solid tumours. Standard curative procedures across Noida centres include breast conservation surgery with sentinel lymph node biopsy validated by NSABP B-32 and ACOSOG Z0011, modified radical mastectomy, composite resection with pedicled or free flap reconstruction for oral cavity cancer, transoral robotic surgery for select oropharyngeal carcinoma at a leading cancer centre Sector 128, radical and partial nephrectomy, VATS or robotic lobectomy per CALGB 140503 and JCOG 0802, D2 gastrectomy per JCOG 9501 and the Dutch D1D2 trial, Whipple pancreaticoduodenectomy at a leading cancer centre and a leading cancer centre, hepatic resection per BCLC, laparoscopic and robotic colectomy and LAR with TME, debulking for advanced ovarian cancer per EORTC 55971 and CHORUS, and radical hysterectomy with the caveat of the LACC trial findings. For cytoreductive surgery with HIPEC, Noida patients are referred to leading cancer centres, or a leading cancer centre. For complex hepatopancreatobiliary resections beyond Noida scope, referral to leading cancer centres, or a leading cancer centre is established (see a tertiary cancer centre EBM surgical chapters and NCI PDQ surgical treatment guidance).
Radiation Oncology in Noida: IMRT, SBRT, Brachytherapy, and Proton Referral
Radiation oncology in Noida is delivered on linear accelerators at a leading cancer centre Sector 128 (TrueBeam STx with IMRT, VMAT, SBRT, SRS, and image-guided radiotherapy), a leading cancer centre Sector 62 (IMRT and IGRT), Metro Sector 11 (TrueBeam LINAC), and Yatharth Sector 110 (IMRT, IGRT, SBRT). a leading cancer centre Sector 128 also carries HDR Ir-192 brachytherapy for cervix, endometrium, vagina, and breast APBI per ICRU 89 and EMBRACE-II. Sharda Greater Noida runs radiation oncology with PET-CT-guided planning (see IAEA/ICRU 89 brachytherapy standards). Noida does not currently host CyberKnife, Tomotherapy, or MRI-LINAC; patients are referred to a leading cancer centre Indraprastha (CyberKnife), a leading cancer centre Gurgaon (CyberKnife), or a leading cancer centre (Tomotherapy). Proton therapy is referred to a leading cancer centre Proton Chennai per PTCOG (see NCI PDQ proton therapy).
Standard fractionation regimens in Noida include 40 Gy in 15 fractions hypofractionated whole breast per START B and 26 Gy in 5 fractions per FAST-Forward; 45 to 50.4 Gy concurrent chemoradiation for cervix with HDR brachytherapy per EMBRACE-I and EMBRACE-II at a leading cancer centre Sector 128; 70 Gy in 35 fractions concurrent CRT for head and neck per RTOG 9501 and Bonner cetuximab-RT; 60 Gy in 30 fractions concurrent CRT for stage III NSCLC followed by consolidation durvalumab per PACIFIC; 54 Gy in 30 fractions with concurrent and adjuvant temozolomide per Stupp for glioblastoma; 25 Gy in 5 fractions short-course and 45 Gy in 25 fractions long-course CRT for rectal cancer with TNT per RAPIDO and PRODIGE 23; SBRT 50 to 60 Gy in 3 to 5 fractions for early NSCLC per RTOG 0236 and CHISEL and for liver oligometastases at a leading cancer centre Sector 128; and palliative 20 Gy in 5 fractions or 8 Gy single fraction for bone metastases per the Dutch Bone Metastasis Study (see NCI PDQ radiotherapy sections).
Medical Oncology in Noida: Chemotherapy Backbones and Biosimilars
Medical oncology day-care chemotherapy units operate at a leading cancer centre Sector 62 (40-bedded facility), a leading cancer centre Sector 128, Metro Sector 11, Yatharth Sector 110, a leading cancer centre Sector 128, Felix Sector 137, and Sharda Greater Noida. Indian biosimilars from Biocon, Hetero, Zydus, Cipla, Dr Reddy’s, Natco, Reliance Life Sciences, and Lupin are used alongside originator molecules at all Noida tertiary centres. Backbone regimens include AC-T and TCHP for breast cancer per BCIRG 006, APHINITY, KATHERINE, and KEYNOTE-522; FOLFOX, CAPOX, FOLFIRI, and FOLFOXIRI plus bevacizumab biosimilar for colorectal cancer per MOSAIC, IDEA, TRIBE, CALGB 80405, FIRE-3, and PARADIGM; FLOT4 for gastric cancer; gemcitabine-cisplatin for biliary tract per ABC-02 with durvalumab per TOPAZ-1; gemcitabine plus nab-paclitaxel and FOLFIRINOX for pancreatic cancer per MPACT and PRODIGE 24; cisplatin-etoposide for SCLC with atezolizumab per IMpower133 and durvalumab per CASPIAN; carboplatin-paclitaxel with PARP maintenance per SOLO-1, PAOLA-1, and PRIMA for ovarian cancer; BEP for testicular GCT per IGCCCG; ABVD and BV-AVD per ECHELON-1 for Hodgkin lymphoma; R-CHOP and Pola-R-CHP per POLARIX for DLBCL; Dara-VRd per GRIFFIN and PERSEUS for myeloma; 7+3 induction for AML per ELN 2022 with venetoclax-azacitidine per VIALE-A; and BFM/MCP-841 protocols for paediatric ALL with blinatumomab per TOWER and inotuzumab per INO-VATE for relapsed disease (see NCI PDQ systemic therapy summaries).
Targeted Therapy and Immunotherapy Across Noida Cancer Centres
Targeted therapy and immune checkpoint inhibitors in Noida practice include trastuzumab biosimilars (Biocon CANMAb, Hetero, Zydus), pertuzumab, T-DM1, trastuzumab deruxtecan per DESTINY-Breast03/04/Gastric01/Lung02, sacituzumab govitecan per ASCENT; CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib per PALOMA-2, MONALEESA-2/3/7, MONARCH 3, and monarchE; PARP inhibitors olaparib, talazoparib, niraparib, and rucaparib per OlympiA, OlympiAD, EMBRACA, PROfound, PROpel, MAGNITUDE, TALAPRO-2, SOLO-1, PAOLA-1, and PRIMA; EGFR TKIs osimertinib per FLAURA/FLAURA2/ADAURA/LAURA, ALK TKIs alectinib per ALEX and lorlatinib per CROWN, ROS1 repotrectinib per TRIDENT-1; BRAF/MEK dabrafenib-trametinib per COMBI-d/v and encorafenib-cetuximab per BEACON CRC; KRAS G12C inhibitors sotorasib and adagrasib per CodeBreaK 200/300 and KRYSTAL-1; MET inhibitors per GEOMETRY mono-1 and VISION; RET inhibitors per LIBRETTO-001 and ARROW; NTRK inhibitors larotrectinib and entrectinib; HER2 tucatinib per HER2CLIMB and MOUNTAINEER; BTK inhibitors ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib per RESONATE-2, ELEVATE-TN, SEQUOIA, and BRUIN; BCL-2 inhibitor venetoclax per CLL14 and MURANO; bispecific T-cell engagers blinatumomab, mosunetuzumab, glofitamab, epcoritamab, teclistamab, talquetamab, and elranatamab; and immune checkpoint inhibitors pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab, cemiplimab, dostarlimab, and tremelimumab across KEYNOTE-024/189/407/048/355/522/590/826/859/A18/564, CheckMate 9LA/816/649/67T/141, IMpower010/110/133, PACIFIC, ADRIATIC, EMPOWER-Lung 1, RUBY, and HIMALAYA (see ESMO clinical practice guidelines and NCI PDQ targeted therapy sections).
Bone Marrow Transplant, CAR-T Cell Therapy, and Theranostics in Noida
Metro Sector 11 and a leading cancer centre Sector 128 both operate bone marrow transplant programmes covering autologous and allogeneic (matched sibling, matched unrelated donor, and haploidentical) haematopoietic stem cell transplantation per EBMT and ASTCT criteria. Yatharth Sector 110 runs a BMT unit under its Centre for Cancer and Bone Marrow Transplant. For complex transplant scenarios including cord blood transplants, referral to a tertiary cancer centre BMT, a tertiary cancer centre BMT, a leading cancer centre BMT, a leading cancer centre BMT, a leading cancer centre Gurgaon, or a tertiary cancer centre ACTREC remains an established route (see NCI PDQ on HCT). CAR-T cell therapy in India includes the indigenous NexCAR19 (actalycabtagene autoleucel) developed by IIT Bombay and a tertiary cancer centre with ImmunoACT, approved by CDSCO, plus access pathways for axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel validated by ZUMA-1/2/5/7, ELIANA, JULIET, TRANSCEND, KarMMa, and CARTITUDE-1/4; Noida patients access CAR-T through NCR referral centres (see NCI PDQ on CAR-T). Theranostics with 177Lu-DOTATATE (PRRT) per NETTER-1 and 177Lu-PSMA-617 per VISION and TheraP are accessed through Metro Sector 11 theranostics service and NCR referral at a tertiary cancer centre Nuclear Medicine, INMAS, leading cancer centres, and a leading cancer centre. Radium-223 per ALSYMPCA and Y-90 SIRT per SIRFLOX/FOXFIRE are available at select NCR centres (see NCI PDQ theranostics references).
Supportive, Palliative, and Survivorship Care in Noida
Supportive and palliative care for Noida patients follows WHO and ESMO standards and the National Programme for Palliative Care under the National Health Mission. CanSupport, the home-based hospice network operating across Delhi, Gurgaon, and Noida, provides at-home palliative nursing, symptom management, counselling, and bereavement support. Pallium India referral pathways, the Cipla Palliative Care Centre referral, the Indian Cancer Society Delhi, CanKids KidsCan paediatric psychosocial support, Cuddles Foundation paediatric nutrition, and Ugam Childhood Cancer Survivors network all serve Noida families through NCR outreach. a leading cancer centre Sector 128 and a leading cancer centre Sector 62 run in-house palliative care and pain management services. Pain management follows the WHO analgesic ladder with oral morphine, supported by the 2014 NDPS Amendment that simplified opioid access across India. Oncology rehabilitation, lymphoedema care per ISL, onco-fertility counselling and gamete cryopreservation per ESHRE and ASCO, cardio-oncology surveillance per ESC and ASCO, oncology nutrition per ASPEN/ESPEN, and survivorship clinics are accessed at a leading cancer centre Sector 128, Metro Sector 11, and through the wider NCR referral network (see a tertiary cancer centre EBM supportive care chapters).
Indicative Cost of Cancer Diagnosis and Imaging in Noida
Costs below are indicative 2025 to 2026 ranges collated from published a tertiary cancer centre reference pricing, CGHS package rates, Ayushman Bharat PMJAY Health Benefit Package 2022 oncology codes, and publicly listed package grids at NCR tertiary hospitals. Ranges span from a public or trust-subsidised pathway at leading cancer centres in the region, and a tertiary cancer centre through to a private package at a leading cancer centre Sector 128, a leading cancer centre Sector 62, Metro Sector 11, Yatharth Sector 110, a leading cancer centre Sector 128, and Sharda Greater Noida. Costs move with the specific regimen, stage, body surface area, length of stay, room category, choice of biosimilar versus originator, and entitlement status. A Noida resident should note that Delhi Arogya Kosh is restricted to residents holding a Delhi address proof; Gautam Buddh Nagar residents are not eligible. The corresponding UP state pathway runs through PMJAY, the UP Mukhyamantri Jan Arogya Yojana, and Rashtriya Arogya Nidhi (see NHA PMJAY HBP 2022 and MoHFW scheme guidelines).
Diagnostic workup for a newly suspected solid tumour, including contrast CT, tumour-marker panel, core biopsy under image guidance, histopathology with a standard IHC panel, and MDT review, lands between roughly 18,000 and 95,000 rupees across NCR. Whole-body FDG PET-CT ranges between roughly 15,000 and 28,000 rupees. PSMA PET-CT for prostate staging ranges between roughly 18,000 and 32,000 rupees. DOTANOC PET-CT for neuroendocrine tumours ranges between roughly 20,000 and 35,000 rupees. NGS solid-tumour panels run between roughly 28,000 and 1,80,000 rupees depending on gene count and RNA fusion testing. BRCA1/BRCA2 and multigene hereditary panels run between roughly 18,000 and 55,000 rupees. At a leading cancer centre Sector 62, a leading cancer centre Sector 128, and Metro Sector 11, these molecular tests are billed through in-house molecular pathology or through external referral laboratories such as MedGenome, Strand Life Sciences, accredited diagnostic laboratories, and accredited diagnostic laboratories (see Rajput et al., cost of cancer care in India and Nair et al., OOPE in public hospitals).
Indicative Cost of Cancer Surgery in Noida
Curative-intent surgery package ranges applicable to Noida private hospitals and the wider NCR referral corridor: breast conservation with SLNB and frozen section sits between roughly 1,10,000 and 3,80,000 rupees. Modified radical mastectomy with axillary clearance sits between roughly 1,50,000 and 4,20,000 rupees. Oncoplastic reconstruction adds between 80,000 and 3,00,000 rupees. Robot-assisted radical prostatectomy at a leading cancer centre Sector 128 on the Da Vinci Xi sits between roughly 3,50,000 and 9,50,000 rupees. Radical or partial nephrectomy sits between roughly 2,20,000 and 7,50,000 rupees. VATS or robotic lobectomy for early NSCLC sits between roughly 3,50,000 and 9,00,000 rupees. D2 gastrectomy sits between roughly 2,80,000 and 7,50,000 rupees. Whipple pancreaticoduodenectomy at a leading cancer centre or a leading cancer centre sits between roughly 3,50,000 and 10,00,000 rupees. Hepatic resection sits between roughly 3,50,000 and 11,00,000 rupees. Laparoscopic or robotic colectomy sits between roughly 2,20,000 and 6,50,000 rupees. LAR with TME sits between roughly 2,80,000 and 7,50,000 rupees. CRS with HIPEC, referred to leading cancer centres, or a leading cancer centre, sits between roughly 6,50,000 and 14,00,000 rupees. Debulking for ovarian cancer sits between roughly 2,50,000 and 7,50,000 rupees. Radical hysterectomy sits between roughly 2,00,000 and 5,50,000 rupees. Composite resection with free flap for oral cancer at a leading cancer centre Sector 62 or a leading cancer centre Sector 128 sits between roughly 3,50,000 and 9,50,000 rupees (see a tertiary cancer centre reference pricing and NCI PDQ).
Indicative Cost of Radiation Therapy in Noida
A full course of 3D-CRT for a standard site sits between roughly 1,10,000 and 3,50,000 rupees. IMRT or VMAT at a leading cancer centre Sector 128 TrueBeam STx, a leading cancer centre Sector 62, or Metro Sector 11 TrueBeam LINAC sits between roughly 1,80,000 and 5,50,000 rupees. IGRT adds roughly 15,000 to 45,000 rupees per course. SBRT for early NSCLC, oligometastatic disease, or HCC at a leading cancer centre Sector 128 or Yatharth Sector 110 sits between roughly 2,00,000 and 6,50,000 rupees. Stereotactic radiosurgery on CyberKnife, not currently available in Noida and accessed via NCR referral to a leading cancer centre Indraprastha or a leading cancer centre Gurgaon, sits between roughly 2,50,000 and 7,50,000 rupees. HDR brachytherapy for cervical cancer per the EMBRACE-II framework at a leading cancer centre Sector 128 sits between roughly 55,000 and 2,20,000 rupees for a full course (see NCI PDQ radiotherapy cost context and Panda et al., economic burden of head and neck cancer treatment).
Indicative Cost of Systemic, Targeted, and Immune Therapy in Noida
Systemic therapy per cycle on biosimilar pricing at Noida day-care units: CAPOX roughly 12,000 to 45,000 rupees, FOLFOX roughly 15,000 to 55,000 rupees, FOLFIRINOX roughly 25,000 to 75,000 rupees, AC-T roughly 10,000 to 35,000 rupees, TCHP roughly 35,000 to 1,10,000 rupees on Indian biosimilars from Biocon, Hetero, or Zydus and roughly 65,000 to 2,20,000 rupees on originator, FLOT4 roughly 14,000 to 45,000 rupees, R-CHOP roughly 25,000 to 75,000 rupees, Pola-R-CHP roughly 2,80,000 to 5,20,000 rupees. Targeted and immune therapy monthly ranges: osimertinib roughly 1,10,000 to 3,20,000 rupees with generic and patient assistance pathways, imatinib under a leading cancer centre Foundation GIPAP free to eligible CML patients at a tertiary cancer centre and linked NCR centres, pembrolizumab per 3-weekly cycle roughly 1,75,000 to 3,50,000 rupees, nivolumab per 2-weekly cycle roughly 90,000 to 2,20,000 rupees, trastuzumab deruxtecan per cycle roughly 4,50,000 to 8,50,000 rupees, sacituzumab govitecan per cycle roughly 4,20,000 to 7,80,000 rupees. Cellular therapy: autologous SCT at Metro Sector 11 or a leading cancer centre Sector 128 roughly 8,00,000 to 22,00,000 rupees, allogeneic SCT roughly 15,00,000 to 45,00,000 rupees, NexCAR19 CAR-T roughly 30,00,000 to 42,00,000 rupees. Theranostics: 177Lu-DOTATATE per cycle roughly 4,50,000 to 7,50,000 rupees, 177Lu-PSMA-617 per cycle roughly 4,50,000 to 7,80,000 rupees, Y-90 SIRT roughly 9,50,000 to 18,00,000 rupees (see NHA PMJAY oncology codes, MoHFW CGHS rates, and Geldsetzer et al., financial toxicity of cancer treatment in India).
Entitlements and Financial Support: PMJAY, CGHS, UP Mukhyamantri Jan Arogya Yojana, and Charity Pathways
PMJAY covers oncology under the Health Benefit Package 2022 with defined package rates for surgery, chemotherapy, radiation, and supportive care at empanelled hospitals; Noida residents with Ayushman Bharat cards can access this at empanelled centres including leading cancer centres, and a tertiary cancer centre in Delhi and empanelled private hospitals in Noida (see NHA PMJAY HBP 2022 and PMJAY empanelment portal). CGHS beneficiaries residing in Noida are covered at CGHS-empanelled hospitals in the Delhi NCR zone. ECHS covers ex-servicemen and dependants. ESIC covers eligible insured workers and dependants, and Noida’s industrial workforce includes a substantial ESIC-eligible population (see ESIC). The UP Mukhyamantri Jan Arogya Yojana extends coverage to families not covered under PMJAY but meeting the state’s expanded eligibility threshold. Rashtriya Arogya Nidhi provides one-time financial assistance of up to 15,00,000 rupees for BPL patients undergoing treatment at government hospitals for life-threatening diseases including cancer (see MoHFW RAN guidelines). The Health Minister’s Cancer Patient Fund and the Prime Minister’s National Relief Fund offer case-based grants for indigent patients at a tertiary cancer centre and other central institutions. Hospital-based charity pools at a leading cancer centre, a leading cancer centre, and Sharda, the Indian Cancer Society, CanKids KidsCan, and CanSupport extend means-tested support. Patients should request a written, itemised estimate and a package-versus-non-package comparison before admission, and should ask whether a biosimilar substitution is acceptable for trastuzumab, rituximab, bevacizumab, pegfilgrastim, and pertuzumab, since this single decision often halves systemic therapy cost without loss of efficacy as accepted by Indian regulators (see WHO biosimilar prequalification).
Patient and Family FAQs: First Week, Second Opinions, Public Versus Private, and Financial Planning
How should a Noida resident with a new suspicion of cancer approach the first week? Request the referring physician to write a provisional diagnosis and a clear next-step list. Consolidate prior imaging, blood work, and any biopsy slides and blocks into a single folder, since NCR tumour boards will ask for blocks for central review. Book an appointment at a tertiary unit: a leading cancer centre Sector 62 Cancer Institute, a leading cancer centre Sector 128 Cancer Centre, Metro Sector 11, Yatharth Sector 110, or Sharda Greater Noida for the private pathway, or register at a tertiary cancer centre OPD, a tertiary cancer centre, a tertiary cancer centre, or a tertiary cancer centre for the public pathway. Ask the treating unit to present the case at a multidisciplinary tumour board before any cancer-directed therapy starts, in line with ESMO and NCCN practice.
Is a second opinion appropriate? A second opinion is a normal part of cancer care and is welcomed by NCR tertiary centres. From Noida, a formal second opinion can be obtained at a tertiary cancer centre, a tertiary cancer centre Rohini, a leading cancer centre Gurgaon, a leading cancer centre Saket, a leading cancer centre, a leading cancer centre Gurgaon, or a leading cancer centre Indraprastha, or by sending blocks and reports to a tertiary cancer centre for a central pathology review. A second opinion is specifically worth requesting before major surgery such as Whipple, hepatic resection, or CRS with HIPEC; before starting a high-cost targeted therapy where the molecular target must be confirmed; before a decision to escalate to allogeneic transplant or CAR-T; and whenever the proposed plan deviates from NCCN or ESMO standard-of-care pathways.
Public or private: which is right for a Noida family? A Noida resident with limited means who qualifies for PMJAY, CGHS, ECHS, or ESIC can access internationally benchmarked oncology care at leading cancer centres in the region, and a tertiary cancer centre at subsidised or nil out-of-pocket cost, with the tradeoff that waiting times for elective imaging, surgery, or radiotherapy may run from several weeks to a few months. The referral from Gautam Buddh Nagar to these Delhi public centres crosses the Yamuna and adds travel time, particularly during winter months with restricted visibility and congestion on the DND Flyway and Noida-Delhi Link roads. A patient with insurance, corporate cover, or private means may prefer a Noida tertiary hospital for proximity, faster scheduling, and the full range of robotic surgery, SBRT, and transplant services. Many Noida families use a hybrid pathway: initial biopsy and diagnosis in a private Noida hospital, surgery in the same centre when speed is critical, and systemic therapy shared between a public a tertiary cancer centre day-care slot and a private Noida satellite closer to home.
Does Noida have a government cancer hospital? Gautam Buddh Nagar does not have a standalone government cancer centre or a government medical college hospital with a structured oncology department offering surgery, chemotherapy, and radiation under one roof. The Government District Hospital at Sector 30 provides primary and secondary care but not tertiary oncology. ICMR-NICPR at Sector 39 is a research and screening institute, not a treatment hospital. For public-sector cancer treatment, Noida residents are referred to a tertiary cancer centre Delhi, NCI Jhajjar, a tertiary cancer centre, a tertiary cancer centre, or a tertiary cancer centre.
How to verify a doctor and an institution? Verify the oncologist’s registration on the Uttar Pradesh Medical Council online register and check the NMC national register for recognised postgraduate qualifications (MD, DM Medical Oncology, MCh Surgical Oncology, MD Radiation Oncology, DrNB). Prefer hospitals accredited by NABH and laboratories accredited by NABL. Among Noida hospitals, a leading cancer centre Sector 128, a leading cancer centre Sector 62, Kailash Sector 27, Metro Sector 11, and Sharda Greater Noida carry NABH or equivalent accreditation.
How to decide between a biosimilar and an originator biologic? Indian biosimilars of trastuzumab, rituximab, bevacizumab, pegfilgrastim, and pertuzumab are approved by CDSCO and are used routinely at a tertiary cancer centre and at Noida private centres including a leading cancer centre Sector 128, a leading cancer centre Sector 62, and Metro Sector 11. For most indications the clinical efficacy is considered equivalent at substantially lower cost, and patients should feel comfortable requesting a biosimilar option explicitly when reviewing the treatment plan and the itemised estimate.
Can a Noida resident access ICMR-NICPR for screening? ICMR-NICPR at Sector 39 runs free population-based cancer screening camps at PHCs and CHCs across Gautam Buddh Nagar for oral, breast, and cervical cancer. It also runs the district’s Population Based Cancer Registry. NICPR does not provide cancer treatment, but can refer patients with screen-detected abnormalities to tertiary centres in Noida or Delhi (see NICPR registry).
What if treatment requires a modality not available in Noida? For proton therapy, referral runs to a leading cancer centre Proton Cancer Centre in Chennai. For CyberKnife, referral runs to a leading cancer centre Indraprastha Delhi or a leading cancer centre Gurgaon. For MRI-LINAC, referral runs to centres in the wider NCR. For CRS with HIPEC, referral runs to leading cancer centres, or a leading cancer centre. For complex haplo-identical or cord blood transplants, referral runs to a tertiary cancer centre BMT, a tertiary cancer centre BMT, a leading cancer centre BMT, or a tertiary cancer centre ACTREC Mumbai. The treating oncologist at a Noida hospital will typically initiate the referral, and the receiving centre will accept the transfer with prior medical records and block shipment.
How to organise travel and caregiving for families coming to Noida from western UP? Families from Bulandshahr, Aligarh, Agra, Meerut, and other western UP districts routinely travel into Noida for tertiary cancer care. Budget guest houses and paying-guest accommodation are available near the Sector 128 hospital corridor and in older Noida sectors. CanSupport and the Indian Cancer Society can assist with practical support across the NCR. Families should plan for a minimum of two caregivers in rotation, one medical file custodian with copies of every report and a dated event log, and a single WhatsApp group with the treating unit’s coordinator for appointment updates.
How to plan finances and insurance? Review the health insurance policy for oncology coverage, waiting periods, room-rent limits, co-pay clauses, and whether day-care chemotherapy is covered. Ask the hospital’s billing desk for a written estimate before admission and request a cashless pre-authorisation where applicable. Check PMJAY, CGHS, ECHS, ESIC, and UP Mukhyamantri Jan Arogya Yojana eligibility in parallel. For high-cost drugs, ask the treating oncologist to link the patient to manufacturer patient assistance programmes: a leading cancer centre Foundation GIPAP for imatinib, and assistance pathways for trastuzumab, osimertinib, ibrutinib, venetoclax, and pembrolizumab (see NHA PMJAY and MoHFW HMCPF/RAN).
What questions should be asked at every tumour-board decision point? What is the TNM or site-specific stage? What is the biomarker panel and has reflex testing been done per ESMO and NCCN guidance? Is surgery curative-intent or palliative? Is neoadjuvant therapy indicated? What is the expected benefit in absolute terms? What are the side effects and how will they be monitored? Is there a clinical trial to consider? What is the palliative and supportive care plan? What is the follow-up surveillance plan per ESMO and NCCN? What is the written cost estimate and are biosimilar substitutions available? (See ESMO clinical practice guidelines.)